Home Cart Sign in  
Chemical Structure| 615-18-9 Chemical Structure| 615-18-9

Structure of 2-Chlorobenzoxazole
CAS No.: 615-18-9

Chemical Structure| 615-18-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 615-18-9 ]

CAS No. :615-18-9
Formula : C7H4ClNO
M.W : 153.57
SMILES Code : C1=CC=CC2=C1N=C(Cl)O2
MDL No. :MFCD00005766
InChI Key :BBVQDWDBTWSGHQ-UHFFFAOYSA-N
Pubchem ID :11986

Safety of [ 615-18-9 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Computational Chemistry of [ 615-18-9 ] Show Less

Physicochemical Properties

Num. heavy atoms 10
Num. arom. heavy atoms 9
Fraction Csp3 0.0
Num. rotatable bonds 0
Num. H-bond acceptors 2.0
Num. H-bond donors 0.0
Molar Refractivity 39.02
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

26.03 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.12
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.84
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.48
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.58
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.58
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.32

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.25
Solubility 0.0869 mg/ml ; 0.000566 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-3.04
Solubility 0.138 mg/ml ; 0.000902 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.51
Solubility 0.047 mg/ml ; 0.000306 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.22 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.22

Application In Synthesis of [ 615-18-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 615-18-9 ]

[ 615-18-9 ] Synthesis Path-Downstream   1~10

  • 1
  • [ 615-18-9 ]
  • [ 81-16-3 ]
  • [ 20495-70-9 ]
  • 2
  • [ 110-85-0 ]
  • [ 615-18-9 ]
  • [ 111628-39-8 ]
YieldReaction ConditionsOperation in experiment
75% With triethylamine; In dichloromethane; water; at 0℃; for 0.5h; 5.6g (65 mmol) Piperazine (water free) and 3.27g (0.325 mol) triethylamine was dissolved in 50 ml of dry CH2Cl2 and the solution cooled to 0C in an ice/salt bath. 2-Chlorobenzoxazole (4d) dissolved in 20 ml of dry CH2Cl2 was added dropwise to the solution under stirring keeping the solution at 0C. After the addition, the mixture was stirred for a further 30 min at 0C and then quenched with 200 ml of ice-water. After separation of the organic phase, the water phase was extracted with ethyl acetate (2 x 100 ml), the combined organic phases was washed with sat. NaCl solution, dried over anhyd. Na2SO4, filtered and evaporated to dryness. Compound 8d was isolated as a white solid over column chromatography using silica gel with CH2Cl2/MeOH (5:1) as eluent. Yield 4.96 g (75%). 1HNMR (δ ppm): 3.48-3.53 (m, 4H, PZI); 3.17 (s, 1H, NH); 2.75-2.80 (m, 4H, PZI); 6.99 (dt, J=1.6Hz, J=8Hz, 1H, BZO-H5); 7.18 (dt, J=1.2Hz, J=7.6Hz, 1H, BZO-H6); 7.27 (dd, J=1.4Hz, J=7.6Hz, 1H, BZO-H7); 7.37 (dd, J=0.6Hz, J=7.8Hz, 1H, BZO-H4).
75% With triethylamine; In dichloromethane; at 0℃; 5.6g (65 mM) Piperazine (water free) and3.27g (0.325 mol) triethylamine was dissolved in 50 ml of dry CH2Cl2 and the solution cooledto 0C in an ice/salt bath. 2-Chlorobenzoxazole (1c) dissolved in 20 mL of dry CH2Cl2 wasadded dropwise to the solution under stirring keeping the solution at 0C. After the addition,the mixture was stirred for a further 30 min at 0C and then quenched with 200 mL of icewater.After separation of the organic phase, the water phase was extracted with ethyl acetate(2 x 100 mL), the combined organic phases was washed with sat. NaCl solution, dried overanhyd. Na2SO4, filtered and evaporated to dryness. Compound 8d was isolated as a white solidover column chromatography using silica gel with CH2Cl2/MeOH (5:1) as eluent. Yield 4.96 g(75%). 1H NMR (200 MHz, d6-DMSO, d): 3.48-3.53 (m, 4H, 4x Pip-H); 3.17 (s, 1H, NH);2.75-2.80 (m, 4H, 4x Pip-H); 6.99 (dt, J = 1.6Hz, J = 8Hz, 1H, BZO-H5); 7.18 (dt, J = 1.2Hz,J = 7.6Hz, 1H, BZO-H6); 7.27 (dd, J = 1.4Hz, J = 7.6Hz, 1H, BZO-H7); 7.37 (dd, J = 0.6Hz,J = 7.8Hz, 1H, BZO-H4).
72% In N,N-dimethyl-formamide; at 90℃; for 3h;Inert atmosphere; A solution of piperazine (0.7 g, 8.2 mmol, 2.5 eq.) and 2-chlorobenzoxazole (0.5 g, 3.27 mmol) in dry DMF (10 mL) was stirred at 90 C for 3 hours under inert conditions. After the mixture was allowed to cool down, water (10mL) was added and the mixture was acidified to pH 2 with concentrated HCI prior to be washed with DCM (2X20 mL). The aqueous phase was adjusted to pH 12 with NaOH 4N and extracted with DCM (3X25 mL). The organic phase was washed with water (4X10 mL), dried over MgS04 and concentrated under reduced pressure to afford 2-piperazin-1 -yl-1 ,3-benzoxazole (0.48 g, 72%). ESI-MS m/z: 204 ([M+H]+ , 100%); RT= 0.9 min(Method 3).
55% With triethylamine; In dichloromethane; at 0℃; for 0.5h; Step l 0.90 g (10.4 mmol) of piperazine was dissolved in 50 ml of dichloromethane in a dried round flask provided with nitrogen gas, 0.80 g (5.2 mmol) of 2-chlorobenzooxazole and 0.9 ml (52.1 mmol) of triethylamine were added thereto at 0C , and the mixture was incubated at 0C for 30 mins. After adding water thereto, the reaction mixture was extracted with ethyl acetate, and the formed organic layer was dried over anhydrous magnesium sulfate and concentrated under a reduced pressure. The resulting residue was subjected to silica gel column chromatography (dichloromethane:methanol=9:l) to obtain 0.58 g of 2-(piperazin-l-yl)benzooxazole (yield: 55%).
With triethylamine; In dichloromethane; water; INVENTIVE EXAMPLE 14 2-(1-Piperazinyl)benzoxazole Anhydrous piperazine (5.6 g) was dissolved in methylene chloride (100 ml) to which was subsequently added triethylamine (4.5 ml). With cooling in an ice bath, to this was added dropwise 2-chlorobenzoxazole (3.7 ml) in small portions, followed by 45 minutes of stirring. The reaction solution was mixed with water, extracted with methylene chloride and then washed with saturated sodium bicarbonate aqueous solution and saturated brine in that order. The organic layer was dried with magnesium sulfate and the solvent was evaporated under a reduced pressure. Thereafter, the thus obtained mixture was purified by a silica gel column chromatography (methanol) to obtain the title compound 2-(1-piperazinyl)benzoxazole (4.751 g) in the form of yellow crystalline powder.
With potassium carbonate;potassium iodide; In methanol; chloroform; acetonitrile; Reference example 16 Synthesis of 1-(2-benzoxazolyl)piperazine STR79 In 200 ml of acetonitrile were dissolved 33.6 g (0.39 mole) of piperazine and 10.0 g (0.065 mole) of 2-chlorobenzoxazole, and 9.0 g (0.065 mole) of potassium carbonate and a catalytic amount of potassium iodide were added thereto. The mixture was refluxed by heating for 11 hours under stirring. The mixture was cooled to room temperature and then filtered. The filtrate was concentrated under reduced pressure, and the residue was applied to silica gel column chromatography (the eluent used was a mixture of chloroform: methanol = 9: 1) to obtain 7.54 g of 1-(2-benzoxazolyl)piperazine as white crystals. MS spectrum (CI): m/e 204 (M+ +1)
In dichloromethane; water; EXAMPLE 10 8-(Benzoxazol-2-yl)-8-aza-5-azoniaspiro[4,5]decane iodide A 3.07 g portion of 2-chlorobenzoxazole was dissolved in 10 ml of dichloromethane. Under cooling with ice, to this was added dropwise 3.45 g of anhydrous piperazine which has been dissolved in 30 ml of dichloromethane, followed by 1 hour of reaction. The reaction solution was concentrated under a reduced pressure, and the resulting residue was purified by a silica gel column chromatography (dichloromethane:methanol=20:1), followed by concentration of the elude under a reduced pressure. Thereafter, the resulting residue was dissolved in 30 ml of water, neutralized with 1N hydrochloric acid, extracted with dichloromethane, washed with water, dehydrated with Na2 SO4 and then concentrated under a reduced pressure to obtain 1.77 g of 2-(1-piperazinyl)benzoxazole.
In ethanol; Preparation 4 1-(Benzoxazol-2-yl)piperazine STR22 To a stirred solution of piperazine (8 g, 93 mmole) in ethanol (30 ml) was added 2-chlorobenzoxazole (3 g, 19.5 mmole) dropwise. The resulting reaction was exothermic. The mixture was then stirred for 18 hours at room temperature, quenched by the addition of methylene chloride (50 ml) and the resulting precipitate removed by filtration. The filtrate was concentrated under reduced pressure then purified by flash column chromatography on silica gel eluding with methylene chloride: methanol: 0.88 ammonia solution (90:10:1) to yield the title compound, m.p. 70-72 (1.8 g, 46%), which was used directly.
With potassium carbonate;potassium iodide; In methanol; chloroform; acetonitrile; (Reference example 16) Synthesis of 1-(2-benzoxazolyl)piperazine 33.6 g (0.39 mol) of piperazine and 10.0 g (0.065 mol) of 2-chlorobenzoxazole were dissolved in 200 ml of acetonitrile, and 9.0 g (0.065 mol) of potassium carbonate and a catalytic amount of potassium iodide were added thereto, followed by heating under reflux with stirring for 11 hours. The reaction mixture was cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure and the residue was subjected to silica gel column chromatography (eluding solution: mixture of chloroform:methanol = 9:1) to obtain 7.54 g of 1-(2-benzoxazolyl)piperazine as white crystals. MS spectrum (CI): m/e 204 (M++1)
With triethylamine; In toluene; at 40℃; for 5h; To a solution of piperazine (2.24 g, 26 mmol, 1 equiv.) in toluene was added 2-chlorobenzoxazole (1.0 g, 6.51 mmol, 1 equiv.), followed by Et3N (3.62 mL, 4 equiv.). The resulting mixture was stirred at 40 C. for 5 hours. The solvent was removed under reduced pressure, and the residue was dissolved in EtOAc. The solution was washed with H2O (*4), brine and dried over Na2SO4. The solvent was evaporated under reduced pressure to afford 0.87 g of intermediate IV-A-17.
In chloroform; at 20℃; for 16h; Step i) To a stirred solution of piperazine (560.9 mg, 6.50 mmol) in CHCl3 (16 ml_) was added 2-chlorobenzoxazole (500 mg, 3.25 mmol) at room temperature. The reaction mixture was stirred at room temperature for 16 hr. CHCl3 was removed and the resulting white solid was dissolved in water. After stirring in water for 30 min, the aqueous layer was extracted with CH2CI2. The combined organic layer was dried over MgSO4, filtered, and concentrated. The white solid (20, 439 mg, 67 %) was used for the next step without purification.

  • 3
  • [ 615-18-9 ]
  • [ 1544-75-8 ]
  • 1-benzooxazol-2-yl-6-fluoro-1,3-dihydro-benzoimidazol-2-one [ No CAS ]
  • 1-benzooxazol-2-yl-5-fluoro-1,3-dihydro-benzoimidazol-2-one [ No CAS ]
  • 4
  • [ 615-18-9 ]
  • [ 18650-39-0 ]
  • [ 256518-55-5 ]
YieldReaction ConditionsOperation in experiment
With N-ethyl-N,N-diisopropylamine; In acetonitrile; Preparation 2 Methyl (2S)-1-(1,3-benzoxazol-2-yl)-2-piperidinecarboxylate Ethyldiisopropylamine (6.52 ml) was added to a solution of (2S)-2-(methoxycarbonyl)piperidinium chloride (3.057 g) [see Preparation 1] and 2-chlorobenzoxazole (2.13 ml) in acetonitrile (50 ml). The reaction mixture was stirred at room temperature for 18 hours and then at 50° C. for a further 2 hours. The solvent was removed under reduced pressure and the residue partitioned between ethyl acetate and water, the organic layer was separated, dried over magnesium sulphate and the solvent removed under reduced pressure. The crude product was purified by column chromatography on silica gel eluding with a solvent gradient of 80:10:0, changing to 0:100:0, followed by 0:95:5, by volume, hexane:ethyl acetate:methanol, to afford methyl (2S)-1-(1,3-benzoxazol-2-yl)-2-piperidinecarboxylate (3.18 g) as a solid. 1H-NMR (CDCl3) delta: 7.35 (1H, d), 7.25 (1H, d), 7.15 (1H, m), 7.00 (1H, m), 5.00 (1H, d), 4.20 (1H, m), 3.70 (3H, s), 3.35 (1H, t), 2.30 (1H, d), 1.80 (3H, m), 1.60 (1H, m), 1.35 (1H, m). MS: 261 (MH+).
  • 5
  • [ 615-18-9 ]
  • [ 18650-39-0 ]
  • [ 7087-68-5 ]
  • [ 256518-55-5 ]
YieldReaction ConditionsOperation in experiment
In acetonitrile; Preparation 2/Example 32 Methyl (2S)-1-(1,3-benzoxazol-2-yl)-2-piperidinecarboxylate STR47 N-Ethyldiisopropylamine (6.52 ml) was added to a solution of (2S)-2-(methoxycarbonyl)piperidinium chloride (3.057 g) [see Preparation 1] and 2-chlorobenzoxazole (2.13 ml) in acetonitrile (50 ml). The reaction mixture was stirred at room temperature for 18 hours and then at 50° C. for a further 2 hours. The solvent was removed under reduced pressure and the residue partitioned between ethyl acetate and water, the organic layer was separated, dried over magnesium sulphate and the solvent removed under reduced pressure. The crude product was purified by column chromatography on silica gel eluding with a solvent gradient of 80:10:0, changing to 0:100:0, followed by 0:95:5, by volume, hexane:ethyl acetate:methanol, to afford methyl (2S)-1-(1,3-benzoxazol-2-yl)-2-piperidinecarboxylate (3.18 g) as a solid. 1 H-NMR (CDCl3)delta:7.35 (1H, d), 7.25 (1H, m), 7.00 (1H, m), 5.00 (1H, d), 4.20 (1H, m), 3.70 (3H, s), 3.35 (1H, t), 2.30 (1H, d), 1.80 (3H, m), 1.60 (1H, m), 1.35 (1H, m). MS:261 (MH+).
  • 6
  • [ 615-18-9 ]
  • [ 121148-00-3 ]
  • methyl (2S,4R)-4-(2-benzoxazolyl)amino-1-tert-butoxycarbonylpyrrolidine-2-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
With triethylamine; In tetrahydrofuran; water; (1) Methyl (2S,4R)-4-amino-1-tert-butoxycarbonylpyrrolidine-2-carboxylate [product of Reference Example 4(2), 3.32 g] and triethylamine (1.4 mL) were dissolved in tetrahydrofuran (20 mL). 2-Chlorobenzoxazole (0.86 mL) was added thereto and the mixture was stirred at room temperature for 48 hr. The reaction mixture was added to water and extracted with ethyl acetate. The extract was washed with saturated aqueous sodium hydrogencarbonate solution and brine, and dried. The solvent was evaporated under reduced pressure and the residue was purified by silica gel chromatography to give methyl (2S,4R)-4-(2-benzoxazolyl)amino-1-tert-butoxycarbonylpyrrolidine-2-carboxylate (1.48 g) as a white solid.
  • 7
  • [ 273-53-0 ]
  • [ 3621-82-7 ]
  • [ 615-18-9 ]
YieldReaction ConditionsOperation in experiment
EXAMPLE 2 Using the method of Example 1, 11.9 g (0.1 mol) of 1,3-benzoxazole were reacted under the same conditions to give 2-chlorobenzoxazole.
  • 8
  • [ 615-18-9 ]
  • [ 2799-07-7 ]
  • [ 1200836-28-7 ]
YieldReaction ConditionsOperation in experiment
Synthetic Example 6; (R)-2-(Benzoxazol-2-ylamino)-3-mercapto-propionic acid hydrochloride; Step 1: (R>2-(Benzoxazol-2-ylaminoV3 -tritylsulfanyl-propionic acid; The mixture of <strong>[2799-07-7]S-trityl-L-cysteine</strong> (5.0 g, 13.76 mmol), 2-chloro-l,3- benzoxazole (2.32 g, 15.11 mmol) and diisopropylethylamine (DIPEA) (9.1 mL, 55.01 mmol) in DMF (20 mL) was heated at 80 0C for 1 h under Ar atmosphere. The mixture was poured into water (100 mL) and acidified by addition of 5percent aqueous KHSO4 to reach pH~3. The product was extracted into EtOAc (2 x 150 mL) and the combined organic phases were washed with water, brine and dried over Na2SO4. The solvent was evaporated to give crude (R)-2-(benzoxazol-2-ylamino)-3-tritylsulfanyl- propionic acid (6.60 g, 100percent), which was used in the next step without purification.
  • 10
  • [ 615-18-9 ]
  • [ 349-58-6 ]
  • 2-(3,5-bis(trifluoromethyl)phenoxy)benzo[d]oxazole [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 615-18-9 ]

Chlorides

Chemical Structure| 3621-81-6

A139721 [3621-81-6]

2,5-Dichlorobenzooxazole

Similarity: 0.88

Chemical Structure| 1030377-54-8

A230759 [1030377-54-8]

5-Bromo-2-chlorobenzo[d]oxazole

Similarity: 0.76

Chemical Structure| 17200-29-2

A137169 [17200-29-2]

5-Chlorobenzoxazole

Similarity: 0.76

Chemical Structure| 41014-43-1

A137513 [41014-43-1]

2-(Chloromethyl)benzo[d]oxazole

Similarity: 0.72

Chemical Structure| 78451-11-3

A194192 [78451-11-3]

Ethyl 2-chloro-4-methyloxazole-5-carboxylate

Similarity: 0.70

Related Parent Nucleus of
[ 615-18-9 ]

Benzoxazoles

Chemical Structure| 3621-81-6

A139721 [3621-81-6]

2,5-Dichlorobenzooxazole

Similarity: 0.88

Chemical Structure| 177492-52-3

A183848 [177492-52-3]

Benzo[d]oxazol-6-amine

Similarity: 0.83

Chemical Structure| 273-53-0

A224260 [273-53-0]

Benzoxazole

Similarity: 0.83

Chemical Structure| 163808-09-1

A224563 [163808-09-1]

4-Aminobenzoxazole

Similarity: 0.78

Chemical Structure| 10531-78-9

A304190 [10531-78-9]

5-Methylbenzo[d]oxazole

Similarity: 0.77